鲍曼不动杆菌肺炎的抗菌药物治疗

Antimicorbial treatment of Acinetobacter baumannii pneumonia

鲍曼不动杆菌感染所致的医院获得性肺炎须引起社会的高度关注。近年来,鲍曼不动杆菌耐药率呈逐年增加的趋势,多重耐药或广泛耐药鲍曼不动杆菌所致医院获得性肺炎的病死率高,因此临床治疗面临很大的抗菌药物选择压力。目前,除多粘菌素和替加环素对鲍曼不动杆菌有较高的敏感性外,其他抗菌药物如舒巴坦、碳青霉烯、喹诺酮和氨基糖苷等耐药率均较高,但可通过增加给药剂量、延长输注时间及联合用药等方式增强药物在体内的敏感性,提高临床治愈率。

Hospital-acquired pneumonia （HAP） caused by Acinetobacter baumannii （AB） should be highly concerned. In recent years, the drug resistant rate of AB has increased year by year. It has been confirmed that the mortality of HAP caused by multidrug-resistant AB or even extensively drug-resistant AB is relatively high, so the selection of antibiotics is a great challenge in clinical practice. At present, AB is only sensitive to polymyxin and tigecycline, and is resistant to most of the other antibiotics including sulbactam, carbapenem, quinolone and aminoglycoside. However, the sensitivity to the antibiotics can be improved by increasing dose, prolonging infusion time, or combining other antibiotics, so as to improve the curative rate.